Compare RNGT & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGT | PLYX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.0M | 271.8M |
| IPO Year | N/A | N/A |
| Metric | RNGT | PLYX |
|---|---|---|
| Price | $10.02 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 85.0K | ★ 545.2K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.20 |
| 52 Week High | $10.05 | $9.18 |
| Indicator | RNGT | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 50.86 |
| Support Level | $9.95 | $4.95 |
| Resistance Level | N/A | $7.43 |
| Average True Range (ATR) | 0.02 | 1.23 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 100.00 | 25.26 |
Range Capital Acquisition Corp II is a blank check company.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.